Literature DB >> 34206428

Th17/Treg-Related Intracellular Signaling in Patients with Chronic Obstructive Pulmonary Disease: Comparison between Local and Systemic Responses.

Juliana D Lourenço1, Walcy R Teodoro2, Denise F Barbeiro3, Ana Paula P Velosa2, Larissa E F Silva1, Júlia B Kohler1, Alyne R Moreira1, Marcelo V Aun4,5, Isadora C da Silva6, Frederico L A Fernandes6, Elnara M Negri7, Jefferson L Gross8, Iolanda F L C Tibério1, Juliana T Ito1, Fernanda D T Q S Lopes1.   

Abstract

Th17/Treg imbalance plays a pivotal role in COPD development and progression. We aimed to assess Th17/Treg-related intracellular signaling at different COPD stages in local and systemic responses. Lung tissue and/or peripheral blood samples were collected and divided into non-obstructed (NOS), COPD stages I and II, and COPD stages III and IV groups. Gene expression of STAT3 and -5, RORγt, Foxp3, interleukin (IL)-6, -17, -10, and TGF-β was assessed by RT-qPCR. IL-6, -17, -10, and TGF-β levels were determined by ELISA. We observed increased STAT3, RORγt, Foxp3, IL-6, and TGF-β gene expression and IL-6 levels in the lungs of COPD I and II patients compared to those of NOS patients. Regarding the systemic response, we observed increased STAT3, RORγt, IL-6, and TGF-β gene expression in the COPD III and IV group and increased IL-6 levels in the COPD I and II group. STAT5 was increased in COPD III and IV patients, although there was a decrease in Foxp3 expression and IL-10 levels in the COPD I and II and COPD III and IV groups, respectively. We demonstrated that an increase in Th17 intracellular signaling in the lungs precedes this increase in the systemic response, whereas Treg intracellular signaling varies between the compartments analyzed in different COPD stages.

Entities:  

Keywords:  COPD; STAT; Th17; Treg; intracellular signaling

Year:  2021        PMID: 34206428     DOI: 10.3390/cells10071569

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  27 in total

1.  Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.

Authors:  Luke M Williams; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2007-01-14       Impact factor: 25.606

2.  Imbalances of Th17 and Treg cells and their respective cytokines in COPD patients by disease stage.

Authors:  Xiang-Nan Li; Xue Pan; Dong Qiu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  The expression of Foxp3 and ROR gamma t in lung tissues from normal smokers and chronic obstructive pulmonary disease patients.

Authors:  Shuyuan Chu; Xiaoning Zhong; Jianquan Zhang; Qifang Lao; Zhiyi He; Jing Bai
Journal:  Int Immunopharmacol       Date:  2011-07-23       Impact factor: 4.932

Review 4.  Cellular and molecular mechanisms of chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  Clin Chest Med       Date:  2013-12-12       Impact factor: 2.878

5.  Disruption of th17/treg balance in the sputum of patients with chronic obstructive pulmonary disease.

Authors:  Haijun Li; Qixiao Liu; Yuanyuan Jiang; Yi Zhang; Yan Zhang; Wei Xiao
Journal:  Am J Med Sci       Date:  2015-05       Impact factor: 2.378

Review 6.  IL-6: regulator of Treg/Th17 balance.

Authors:  Akihiro Kimura; Tadamitsu Kishimoto
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 7.  Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling.

Authors:  Y C Yang; N Zhang; K Van Crombruggen; G H Hu; S L Hong; C Bachert
Journal:  Allergy       Date:  2012-08-23       Impact factor: 13.146

8.  Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease.

Authors:  Huaying Wang; Huajuan Ying; Shi Wang; Xiao Gu; Yuesong Weng; Weidong Peng; Dajing Xia; Wanjun Yu
Journal:  Clin Respir J       Date:  2014-05-21       Impact factor: 2.570

Review 9.  Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.

Authors:  Erin A Marshall; Kevin W Ng; Sonia H Y Kung; Emma M Conway; Victor D Martinez; Elizabeth C Halvorsen; David A Rowbotham; Emily A Vucic; Adam W Plumb; Daiana D Becker-Santos; Katey S S Enfield; Jennifer Y Kennett; Kevin L Bennewith; William W Lockwood; Stephen Lam; John C English; Ninan Abraham; Wan L Lam
Journal:  Mol Cancer       Date:  2016-10-27       Impact factor: 27.401

Review 10.  COPD immunopathology.

Authors:  Gaetano Caramori; Paolo Casolari; Adam Barczyk; Andrew L Durham; Antonino Di Stefano; Ian Adcock
Journal:  Semin Immunopathol       Date:  2016-05-13       Impact factor: 9.623

View more
  5 in total

Review 1.  The role of Th17 cells: explanation of relationship between periodontitis and COPD?

Authors:  Jiaohong Liu; Yuanting Ouyang; Zhiyi Zhang; Siyi Wen; Yixing Pi; Ding Chen; Zhikang Su; Zitian Liang; Lvhua Guo; Yan Wang
Journal:  Inflamm Res       Date:  2022-07-04       Impact factor: 6.986

2.  Evaluation of selected IL6/STAT3 pathway molecules and miRNA expression in chronic obstructive pulmonary disease.

Authors:  J M Kiszałkiewicz; S Majewski; W J Piotrowski; P Górski; D Pastuszak-Lewandoska; M Migdalska-Sęk; E Brzeziańska-Lasota
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

3.  Bufei Decoction Improves Lung-Qi Deficiency Syndrome of Chronic Obstructive Pulmonary Disease in Rats by Regulating the Balance of Th17/Treg Cells.

Authors:  Junxi Shen; Xing Zhu; Yunzhi Chen; Wen Li; Huaiquan Liu; Cancan Chu; Yu Zhang; Changjun Xu; Pingzhen Tong; Xinran Yu; Guangyong Yang; Ying Deng
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-17       Impact factor: 2.650

4.  Editorial: The importance of Th17/Treg imbalance in asthma and COPD development and progression.

Authors:  Fernanda Degobbi T Q S Lopes; Iolanda de Fátima Lopes Calvo Tibério; Adriana Leme; Lucy Fairclough
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 5.  Th17/Treg Imbalance in Chronic Obstructive Pulmonary Disease: Clinical and Experimental Evidence.

Authors:  Juliana Dias Lourenço; Juliana Tiyaki Ito; Milton de Arruda Martins; Iolanda de Fátima Lopes Calvo Tibério; Fernanda Degobbi Tenorio Quirino Dos Santos Lopes
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.